Betting big on Biosimilars: Facility in place - Regulatory and Clinical clearances remain: Eyeing a piece of the US$ 24 Bn biosimilars market by 2019 partnering Mylan, Biocon has 4 molecules in Global Phase-III clinical trials, 1 in RoW Phase-III trials and human insulin eyeing harmonized filings. The Malaysian facility, which will be the focal point for this segment, has commercialized and receivedMalaysian approval, a first in a series of approvals required in next 12-18 months.